Abstract
Background Prader-Willi syndrome (PWS) is a genetic disorder associated with baseline respiratory impairment caused by multiple contributing etiologies. While this may be expected to increase the risk of severe COVID-19 infections in PWS patients, survey studies have suggested paradoxically low disease severity. To better characterize the course of COVID-19 infection in patients with PWS, this study analyzes the outcomes of hospitalizations for COVID-19 among patients with and without PWS.
Methods The National Inpatient Sample, an all-payors administrative claims database of hospitalizations in the United States, was queried for patients with a coded diagnosis COVID-19 in 2020 and 2021. Hospitalizations for patients with PWS compared to those for patients without PWS using Augmented Inverse Propensity Weighting (AIPW).
Results There were 295 (95% CI: 228 to 362) COVID-19 hospitalizations for individuals with PWS and 4,112,400 (95% CI: 4,051,497 to 4,173,303) for individuals without PWS. PWS patients had a median age of 33 years compared to 63 for those without PWS. Individuals with PWS had higher baseline rates of obesity (47.5% vs. 28.4%). AIPW models show that PWS diagnosis is associated with increased hospital length of stay by 7.43 days, hospital charges by $80,126, and the odds of mechanical ventilation and in-hospital death (odds ratios of 1.79 and 1.67, respectively).
Conclusions PWS patients hospitalized with COVID-19 experienced longer hospital stays, higher charges, and increased risk of mechanical ventilation and death. PWS should be considered a risk factor for severe COVID-19, warranting continued protective measures and vaccination efforts. Further research is needed to validate coding for PWS and assess the impact of evolving COVID-19 variants and population immunity on this vulnerable population.
Competing Interest Statement
JL receives funding from Harvard Medical School Dupont Warren Fellowship and Livingston Awards, the Rappaport Foundation, and the Foundation for Prader-Willi Research. He has received equity and consulting fees from Revival Therapeutics, Inc. TVS is an employee of the Foundation for Prader-Willi Research. BBR has no disclosures to report. THM receives funding, through his institution, from National Institute of Health, Telefonica Alfa, InterSystems, Philips Research North America, and honoraria from Springer Nature publishing.
Funding Statement
This work was supported by the National Institute of Mental Health (T32MH112485) and the Foundation for Prader-Willi Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed by the Mass General Brigham Institutional Review Board and classified as Exempt.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data Availability Statement: Publicly available datasets were analyzed in this study. The dataset analyzed for this study can be obtained from the Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality at: https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp
Disclosure: This work was supported by the National Institute of Mental Health (T32MH112485, JL) and the Foundation for Prader-Willi Research.
Conflicts of Interest: JL receives funding from Harvard Medical School Dupont Warren Fellowship and Livingston Awards, the Rappaport Foundation, and the Foundation for Prader-Willi Research. He has received equity and consulting fees from Revival Therapeutics, Inc. TVS is an employee of the Foundation for Prader-Willi Research. BBR has no disclosures to report. THM receives funding, through his institution, from National Institute of Health, Telefonica Alfa, InterSystems, Philips Research North America, and honoraria from Springer Nature publishing.
Data Availability
Publicly available datasets were analyzed in this study. The dataset analyzed for this study can be obtained from the Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality at: https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp
